|Bid||91.00 x 30000|
|Ask||92.50 x 30000|
|Day's Range||90.00 - 90.00|
|52 Week Range||75.00 - 101.00|
|Beta (5Y Monthly)||0.11|
|PE Ratio (TTM)||39.05|
|Forward Dividend & Yield||0.99 (1.06%)|
|Ex-Dividend Date||Mar 04, 2022|
|1y Target Est||N/A|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
Global biotherapeutics leader CSL Behring, a business of CSL, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), for priority review, for etranacogene dezaparvovec (also known as CSL222), an investigational gene therapy for the treatment of adults with hemophilia B. Etranacogene dezaparvovec was specifically designed to make near-normal blood-clotting ability possible by addressing the underlying cause of hemophilia B: a faulty
Walter Charles has been named Senior Vice President and General Manager of CSL Plasma, effective 1 May. He leads the global CSL Plasma organization in driving operational excellence, engaging new and existing donors, and growing its network of centers to collect human plasma that is essential to the manufacturing of life-saving therapies for people in more than 100 countries.